Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Perioperative Ivonescimab + SOX for Locally Advanced Gastric or GEJ Adenocarcinoma
NCT07374250Phase 2Not yet recruiting
- Sponsor
- Sichuan University
- Start
- Feb 2026
- Primary completion
- Dec 2027
- Modality
- Antibody Conjugates, Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of ivonescimab in gastric adenocarcinoma, gastroesophageal junction adenocarcinoma, sponsored by Sichuan University. Planned start Feb 2026; status: not yet recruiting.
02
Drugs
ivonescimab
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on NCT07374250.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07374250.